Boris C. Bastian, MD, PhD: BioMerieux and Other Tests in Melanoma
Which test do you prefer? Is the bioMérieux test preferred, since it detects V600E and K more exclusively?
The bioMerieux test is definitely a step forward in that it basically decreases the number of false negatives. But it’s still missing all the other variants that we discussed earlierV600 mutations that are not E or K or mutations immediately nearby.
CASE: Metastatic Melanoma
Michelle is a 55-year old who was referred by her primary care physician to receive a biopsy for a suspicious mole during a routine visit. Results of the biopsy and other subsequent tests revealed that she had an M1b stage tumor (lung metastasis and a less than ULN LDH level). Her ECOG PS is 0.
- Initial BRAF testing using a laboratory-developed test was negative for BRAF V600E L
She was referred from the community setting to a tertiary center, at which point a second test was conducted using the bioMérieux HxID-BRAF kit. This assay was positive for the BRAF V600K mutation
- Following the finding ofBRAF-positivity, Michelle was prescribed the combination of dabrafenib (150 mg BID) and trametinib (1 mg daily)
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
